NZ565283A - Quinoline derivatives as antibacterial agents - Google Patents

Quinoline derivatives as antibacterial agents

Info

Publication number
NZ565283A
NZ565283A NZ565283A NZ56528306A NZ565283A NZ 565283 A NZ565283 A NZ 565283A NZ 565283 A NZ565283 A NZ 565283A NZ 56528306 A NZ56528306 A NZ 56528306A NZ 565283 A NZ565283 A NZ 565283A
Authority
NZ
New Zealand
Prior art keywords
alkyl
formula
compound
het
use according
Prior art date
Application number
NZ565283A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Jerome Emile Georges Guillemont
Elisabeth Therese Jeanne Pasquier
David Francis Alain Lancois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ565283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ565283A publication Critical patent/NZ565283A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ565283A 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents NZ565283A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107159 2005-08-03
PCT/EP2006/064856 WO2007014940A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterical agents

Publications (1)

Publication Number Publication Date
NZ565283A true NZ565283A (en) 2011-07-29

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ565283A NZ565283A (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterial agents

Country Status (28)

Country Link
US (1) US8017606B2 (enExample)
EP (1) EP1912647B1 (enExample)
JP (1) JP5410753B2 (enExample)
KR (1) KR101337237B1 (enExample)
CN (1) CN101277695B (enExample)
AR (1) AR054889A1 (enExample)
AU (1) AU2006274879B2 (enExample)
BR (1) BRPI0614524B8 (enExample)
CA (1) CA2615901C (enExample)
CY (1) CY1114908T1 (enExample)
DK (1) DK1912647T3 (enExample)
EA (1) EA014832B1 (enExample)
ES (1) ES2437575T3 (enExample)
HR (1) HRP20131116T1 (enExample)
IL (1) IL189141A (enExample)
JO (1) JO2952B1 (enExample)
MX (1) MX2008001602A (enExample)
MY (1) MY148241A (enExample)
NO (1) NO341247B1 (enExample)
NZ (1) NZ565283A (enExample)
PL (1) PL1912647T3 (enExample)
PT (1) PT1912647E (enExample)
RS (1) RS53065B (enExample)
SI (1) SI1912647T1 (enExample)
TW (1) TWI381839B (enExample)
UA (1) UA95916C2 (enExample)
WO (1) WO2007014940A2 (enExample)
ZA (1) ZA200801108B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512364B2 (ja) 1992-03-02 1996-07-03 共栄電工株式会社 筒状の被加工物の内面研磨方法および装置
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
WO2014070760A1 (en) 2012-10-30 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CN105636952A (zh) 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
US20240287022A1 (en) * 2021-06-28 2024-08-29 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) * 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
JP4602903B2 (ja) 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
NZ546990A (en) * 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) * 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
US7902225B2 (en) * 2004-01-23 2011-03-08 Janssen Pharmaceutica Nv Mycobacterial inhibitors
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
JP2009503024A (ja) 2009-01-29
CN101277695A (zh) 2008-10-01
MX2008001602A (es) 2008-02-19
NO341247B1 (no) 2017-09-25
KR101337237B1 (ko) 2013-12-06
RS53065B (sr) 2014-04-30
BRPI0614524B1 (pt) 2020-05-19
WO2007014940A3 (en) 2007-03-29
EA200800501A1 (ru) 2008-10-30
WO2007014940A8 (en) 2007-07-05
HRP20131116T1 (hr) 2013-12-20
EP1912647B1 (en) 2013-09-11
US8017606B2 (en) 2011-09-13
EP1912647A2 (en) 2008-04-23
EA014832B1 (ru) 2011-02-28
PL1912647T3 (pl) 2014-02-28
ZA200801108B (en) 2009-05-27
UA95916C2 (ru) 2011-09-26
JO2952B1 (en) 2016-03-15
IL189141A0 (en) 2008-08-07
CA2615901A1 (en) 2007-02-08
NO20080955L (no) 2008-02-25
AU2006274879B2 (en) 2013-01-10
CY1114908T1 (el) 2016-12-14
AU2006274879A1 (en) 2007-02-08
BRPI0614524A2 (pt) 2011-04-05
AR054889A1 (es) 2007-07-25
KR20080038380A (ko) 2008-05-06
BRPI0614524B8 (pt) 2021-05-25
MY148241A (en) 2013-03-29
TWI381839B (zh) 2013-01-11
US20080255116A1 (en) 2008-10-16
SI1912647T1 (sl) 2014-01-31
TW200744594A (en) 2007-12-16
DK1912647T3 (da) 2013-12-02
PT1912647E (pt) 2013-12-05
CA2615901C (en) 2014-06-03
JP5410753B2 (ja) 2014-02-05
IL189141A (en) 2015-10-29
HK1124233A1 (en) 2009-07-10
WO2007014940A2 (en) 2007-02-08
ES2437575T3 (es) 2014-01-13
CN101277695B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
EP1912647B1 (en) Quinoline derivatives as antibacterical agents
EP1912648B1 (en) Quinoline derivatives as antibacterial agents
EP1901743A1 (en) Quinoline derivatives as antibacterial agents
EP1912649B1 (en) Quinoline derivatives as antibacterial agents
EP1898909A1 (en) Quinoline derivatives as antibacterial agents
EP1898914B1 (en) Quinoline derivatives as antibacterial agents
WO2007000436A1 (en) Quinoline derivatives as antibacterial agents
HK1124233B (en) Quinoline derivatives as antibacterical agents

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 JUL 2016 BY CPA GLOBAL

Effective date: 20130613

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 JUL 2019 BY CPA GLOBAL

Effective date: 20140903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2020 BY CPA GLOBAL

Effective date: 20190613

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2021 BY CPA GLOBAL

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2022 BY CPA GLOBAL

Effective date: 20210617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2023 BY CPA GLOBAL

Effective date: 20220616

LAPS Patent lapsed